Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Bullboard Posts
Comment by RichyRich$on Mar 12, 2016 6:18pm
177 Views
Post# 24652189

RE:RE:RE:RE:What's up?

RE:RE:RE:RE:What's up?I agree SVA.V is on a long-term uptrend with rising bottoms and top since 2009 and should the biotech index drop more, Sernova's positive news to come out soon should buck the trend of any further index drop. But since Mid-2015 it actually didn't buck the trend. SVA.V actually dropped more than the index. SVA.V dropped 48% ($.40 to $.21) while the Biotech Index with IBB dropped only 40% ($400 to $240). So I'm just saying the pullback in the biotech index since Mid-2015 didn't help Sernova find new buyers, since many investors avoid all the biotech stocks if the index is falling and wait until the whole sector starts trending back up again. So this is actually a good thing I'm saying, because it looks like IBB is finished dropping based on technical analysis. That could bring new eyes and buyers to Sernova on top of any momentum from news to come this year, like the U of A end of 4 year human trial results by this summer. One little hint that the U of A trial results should be good, is that if they were bad... Sernova would not have expanded to Massachusetts for further phase human trials. If the results were terrible, they would just let the U of A trial finish up and not expand and make all the aggressive moves and applications they made in 2015. So their aggressive actions looks like the 2012 to 2016 U of A human trials went well.
Bullboard Posts